117 results about "Postmenopausal osteoporosis" patented technology

The invention discloses antibodies that bind high specificity to human RANKL (Receptor Activator for Nuclear Factor kappa B Ligand), wherein, the antibodies are used for the treatment of bone erosion caused by astogeny, hormonotherapy, postmenopausal osteoporosis, bone metastasis, and inflammation. The invention also discloses DNA sequences and supposed amino acid sequences of the antibodies.

The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparation method thereof. In order to overcome the defects in the prior art, the invention provides the traditional Chinese medicine composition which can increase the bone mineral density of a patient suffering from postmenopausal osteoporosis and relieve secondary pain and inflammatory reaction, caused by the postmenopausal osteoporosis. The traditional Chinese medicine composition is mainly prepared from the following raw materials: palmleaf raspberry fruit, atractylodes macrocephala, radix paeoniae alba, tuber fleeceflower root, spina date seed, radix angelicae sinensis, radix codonopsis, radix morindae officinalis, radix acanthopanacis senticosi, rhizoma dioscoreae, poria cocos, radix rehmanniae preparata, radix puerariae, eucommia bark, herba menthae, rhizoma polygonati, fructus ligustri lucidi, epimedium herb, fructus lycii, fructus corni, calcium lactate, semen cuscutae, bovine bone powder, fortune's drynaria rhizome and radix glycyrrhizae. Pharmacological experiments and clinical trials prove that the traditional Chinese medicine composition has a significant effect for treating postmenopausal osteoporosis, so that the traditional Chinese medicine composition has a wide promotion value in the medical field.

The invention discloses a traditional Chinese medical composition for treating postmenopausal osteoporosis and belongs to traditional Chinese medical compositions. The traditional Chinese medical composition for treating postmenopausal osteoporosis comprises herba epimedii, rhizoma cibotii, rhizoma curculiginis, cistanche, Semen Cuscutae, flatstem milkvetch seed, glossy privet fruit, Poria cocos, radix paeoniae alba, radix bupleuri, cassia twig, hairyvein agrimony, the fruit of Chinese wolfberry, dogwood, fried Rhizoma Atractylodis Macrocephalae, Caulis Spatholobi, loranthus parasiticus, prepared fleece flower root, Angelica sinensis and honey-fried licorice root in a certain weight proportion. The traditional Chinese medical composition for treating postmenopausal osteoporosis has the effects of facilitating liver and tonifying kidneys and strengthening tendons and bones, and can be used to effectively treat postmenopausal osteoporosis.

The invention provides a traditional Chinese medicine composition for treating postmenopausal osteoporosis. The traditional Chinese medicine composition comprises medicinal cyathula root, morinda officinalis, drynaria rhizome, cuscuta chinensis, walnut kernel, tortoise shell, herba epimedii, parasitic loranthus, cortex acanthopanacis, fructus ligustri lucidi, hematoxylon, bighead atractylodes rhizome, prepared rehmannia root and ligusticum wallichii. After being adopted for treating postmenopausal osteoporosis, the traditional Chinese medicine composition has the advantages that the side effect is small, the curative effect is good, the cost is low, the cure rate is high, the drug resistance is avoided, the taking is convenient, and the like.

The invention discloses an extraction method and the application of an urogenic stem cell exosome. The extraction method comprises the following specific steps: firstly, collecting urine, then carrying out first-time centrifugation, and adding PBS into a first residual liquid obtained after supernatant is removed; carrying out second-time centrifugation, resuspending the second-time residual liquid obtained after the supernatant is removed through a primary culture medium to obtain urogenic stem cell suspension solution; secondly, carrying out multiplication culture on the urogenic stem cellsand passing down to the second to the sixth generation for later use; thirdly, changing the culture medium obtained in the second step, then continuously culturing, collecting and culturing supernatant, centrifuging, filtering and carrying out centrifugal concentration; adding an exosome extraction reagent for extracting to obtain a resuspension solution of the urogenic stem cells. The urogenic stem cell exosome extracted by the invention is proved by animal experiments to have the advantages of good therapeutic effects on senile osteoporosis, postmenopausal osteoporosis and disuse osteoporosis.

The invention relates to a medicine for treating postmenopausal osteoporosis. The medicine is prepared from the following raw material medicines in parts by weight: 15 parts of Semen Cuscutae, 12 parts of Semen Euryales, 25 parts of medicated leaven, 10 parts of drynaria rhizome, 7 parts of Caulis Spatholobi, 8 parts of Sargent gloryvine, 10 parts of fructus liquidambaris, 12 parts of elderberry, 6 parts of immature tangerine and 5 parts of radix curcumae. The Semen Cuscutae, the Semen Euryales and the medicated leaven have the functions of nourishing liver and kidney and strengthening the spleen and stomach; the drynaria rhizome has the functions of strengthening tendons and bones to treat the root problem; the Caulis Spatholobi, the Sargent gloryvine and the elderberry have the functions of nourishing blood, activating blood and stopping pain; the fructus liquidambaris has the functions of dispelling wind and activating collaterals; the immature tangerine and the chinaberry have the functions of soothing the liver, regulating vital energy and removing stagnation; the medicines are combined for use with the effects of tonifying kidney, strengthening bone, activating blood and stopping pain; and the postmenopausal osteoporosis can be effectively treated.

The invention discloses an application of miR-6802-3p to early diagnosis of postmenopausal osteoporosis. MiRNA with differential expression between a postmenopausal osteoporosis patient and a normal control is screened out by sequencing, then large sample QPCR experiments prove that content of miR-6802-3p in blood of the postmenopausal osteoporosis patient is substantially up-regulated definitely,so that miR-6802-3p can serve as a molecular marker for diagnosing postmenopausal osteoporosis to be used for developing products for diagnosing postmenopausal osteoporosis.

The invention discloses a traditional Chinese medicine composition for treating postmenopausal osteoporosis, belonging to the field of traditional Chinese medicines. For overcoming the shortcomings of the prior art, the invention provides a traditional Chinese medicine that can increase the bone mineral density of a postmenopausal osteoporosis patient and also can relieve secondary pain and inflammatory response caused by postmenopausal osteoporosis. The traditional Chinese medicine composition is prepared from the following raw materials: black false hellebore, ligusticum wallichii, radix paeoniae alba, polygonum multiflorum, radix angelicae, angelica sinensis, codonopsis pilosula, gynostemma pentaphylla, acanthopanax root, the root of red-rooted salvia, poria cocos, prepared rhizome of rehmannia, the root of kudzu vine, asarum, mentha haplocalyx, xanthium sibiricum, glossy privet fruit, herba epimedii, the fruit of Chinese wolfberry, dogwood, radices sileris, the seed of Chinese dodder, bovine-derived power, astragalus membranaceus and liquorice. Pharmacology experiments and clinical experiments prove that the traditional Chinese medicine composition has a remarkable effect for treating postmenopausal osteoporosis, so the traditional Chinese medicine composition has a wide medical promotional value.

The invention relates to application of deferoxamine mesylate, in particular to application of the deferoxamine mesylate in preparing medicaments for treating postmenopausal osteoporosis. The deferoxamine mesylate has low toxicity and safety and can greatly reduce the loss of postmenopausal bone mineral contents.

The invention relates to a traditional Chinese medicine composition for treating postmenopausal osteoporosis, a preparation method and an application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 6-15 parts of eucommia ulmoides, 5-10 parts of fructus rubi and 10-12 parts of semen cuscutae. The traditional Chinese medicine composition has the effects of tonifying liver and kidneys, strengthening bones and muscles, warming yang to reduce urination and delaying senescence, is capable of improving symptoms of soreness and weakness of waist and knees, dizziness, frequent urination and the like, and can be used for successfully treating postmenopausal osteoporosis.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine for treating postmenopausal osteoporosis. The traditional Chinese medicine is prepared from prepared rehmannia, rhizoma cibotii, herba epimedii, fructus psoraleae, oyster, yam, prepared fleece-flower root, eucommia bark, gastrodia elata, medlar, dogwood fruit pulp, radix achyranthis bidentatae, codonopsis pilosula, donkey-hide gelatin, black sesame, parasitic loranthus, glossy privet and schisandra chinensis. The traditional Chinese medicine is in accordance with the theory of traditional Chinese medicinal differentiation, and is combined with the fact that the occurrence of postmenopausal osteoporosis is related to kidney deficiency and spleen deficiency, wherein kidney deficiency is a main pathogenesis of postmenopausal osteoporosis. From the view of traditional Chinese medicine, kidney governs bones and belongs to water in five elements, liver governs tendons and belongs to wood in five elements, so that deficiency of spleen and kidney means the loss of water and wood, which causes that wood is nourished; and tendons and bones are not tonified to cause postmenopausal osteoporosis with the passing of time. Thus, postmenopausal osteoporosis is treated by tonifying spleen and nourishing liver kidney to achieve the fundamental treatment effects of treating both principal and secondary aspect of disease, and preventing relapse.

The invention discloses a traditional Chinese medicine preparation for preventing and treating osteoporosis. The traditional Chinese medicine preparation is prepared from the following crude drugs in parts by weight: 1-10 parts of sea otter, 10-50 parts of epimedium herbs and 10-50 parts of semen cuscutae. Proved by pharmacodynamic study, the traditional Chinese medicine preparation disclosed by the invention can be used for remarkably improving the physiological status of a rat bone with osteoporosis caused by estrogen deficiency, enhancing the strength and toughness of the bone, obviously promoting the bone forming ability of an osteoblast and remarkably inhibiting the bone absorbing ability of an osteoclast so as to have a remarkable effect for preventing and treating postmenopausal osteoporosis. The invention also discloses a preparation method of a traditional Chinese medicine preparation for treating the postmenopausal osteoporosis.

The invention belongs to the field of medicinal preparations, and relates to a lasofoxifene tartrate orally disintegrating tablet for treating postmenopausal osteoporosis and a preparation method thereof. Proper medical auxiliaries are selected according to physicochemical properties of lasofoxifene tartrate, and the orally disintegrating tablet comprises a filling agent, a disintegrating agent, a flavoring agent, a lubricant, a glidant and the like. The medicine can be prepared by granulating and tabletting by a wet method, directly tabletting, or granulating and tabletting by a dry method. The invention aims to provide the lasofoxifene tartrate orally disintegrating tablet with simple preparation process, convenience in administration, quick response to indications, exact curative effect and high bioavailability.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 10 to 20 parts of eucommia ulmoides, 6 to 12 parts of herba epimedii, 5 to 10 parts of safflower carthamus, 5 to 10 parts of rhizoma corydalis, 5 to 10 parts of radix rehmanniae praeparata, 3 to 10 parts of pericarpium citri reticulatae viride, 3 to 10 parts of glossy privet fruit, 3 to 10 parts of rhizoma anemarrhenae, 3 to 6 parts of Chinese yam, 3 to 6 parts of adenophora stricta and 1 to 12 parts of liquorice. The traditional Chinese medicine composition provided by the invention is prepared from the natural traditional Chinese medicinal materials, is small in toxic and side effects, and simple in manufacturing process, has the efficacy of strengthening tendons and bones, activating blood to promote menstruation, nourishing yin and supplementing blood, invigorating spleen and replenishing Qi, and can be used for effectively treating female postmenopausal osteoporosis.

The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating female postmenopausal osteoporosis and a preparing method thereof. The traditional Chinese medicine composition is prepared from, by weight, 10-25 parts of moringa oleifera leaves, 6-15 parts of radix dipsaci, 5-10 parts of codonopsis pilosula, 5-10 parts of rhizoma polygonati, 5-10 parts of radix rehmanniae praeparata, 3-9 parts of caulis spatholobi, 3-9 parts of radix clematidis, 3-9 parts of radix angelicae, 3-6 parts of Chinese yam, 3-6 parts of rhubarb and 1-10 parts of liquorice. The traditional Chinese medicine composition is prepared from natural traditional Chinese medicine, side effect is small, the preparing process is simple, the functions of enriching blood and stopping pain, strengthening tendons and bones, and promoting blood circulation to remove meridian obstruction are realized, and female postmenopausal osteoporosis can be effectively treated.

The invention discloses a medicinal composite containing cornu cervi pantotrichum. The medicinal composite comprises the following components in percentage by weight: 1%-20% of cornu cervi pantotrichum freeze-dried powder, 1%-10% of glucosamine, 1%-20% of collagen, 1%-10% of vitamins B6, 1%-20% of dolomites and 95%-20% of germinated soybean meal, wherein the sum of drugs is 100%; the cornu cervi pantotrichum freeze-dried powder is prepared through the following steps of: freeze-drying fresh cornu cervi pantotrichum, smashing, extracting at 0-4 DEG C by using normal saline, centrifugalizing an extracting solution, and freeze-drying a supernatant into powder. The medicinal composite disclosed by the invention is prepared into a postmenopausal osteoporosis animal model by adopting a ovariotomy method and continuously applied for 12 weeks, is displayed to be used for preventing and treating cancellous bone losing caused due to estrogen reduction through a result and prompted to correct the bone turnover rate enhancement caused due to low estrogen level and improve the coupling unbalance condition of bone absorption and bone formation through a bone metabolism biochemical index and a bone density result, promotes the bone formation and has certain preventing and treating effects on high-turnover type osteoporosis which takes the cancellous bone losing as a main part.

The invention discloses a composition for preventing and treating women postmenopausal osteoporosis which comprises soybean isoflavones, calcium carbonate, vitamin D3, and excipient. The composition is solid state, semi-solid state or liquid state product made by the forms of tablet, capsule, lozenge, pill, granule, and syrup.